Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 353 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: bupropion hydrochloride Clear all

Conditions: Obesity
Interventions: Naltrexone-Bupropion Combination; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression, Side Effects, Sexual Dysfunction, Apathy
Interventions: Wellbutrin XL; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Major Depressive Disorder
Interventions: AXS-05, Bupropion; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 1 more

Conditions: Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions: Bupropion 150 mg XL, Placebo; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 362
States / cities: Anaheim, California • Antioch, California • Baldwin Park, California + 262 more

Conditions: Depression
Interventions: Sertraline, Placebo, BupropionXL; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 296 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 1 more

Conditions: Tobacco Use Disorder
Interventions: Behavioral and pharmacologic tobacco use intervention; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heart Repolarization
Interventions: Naltrexone HCl/bupropion HCl, Placebo, Moxifloxacin; Drug · Other
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions: Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination); Behavioral · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Depression
Interventions: sertraline, bupropion; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Smoking Cessation, Smoking, Tobacco, Mental Illness, Tobacco Use Disorder
Interventions: Videogame-based physical activity, Sedentary videogame, Bupropion, Counseling; Behavioral · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions: Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions: Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 45
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more

Conditions: Smoking, Nicotine Dependence
Interventions: Bupropion; Drug
Lead sponsor: Henry Kranzler; Other
Eligibility: 18 Years and older · Female only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Newark, Delaware • Philadelphia, Pennsylvania

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: TBA-7371, Placebo; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Binge Drinking
Interventions: Naltrexone, Bupropion; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 34 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Smoking Cessation
Interventions: counseling vs. advice; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 80 Years
Enrollment: 689 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Depressive Disorder
Interventions: Extended-release Bupropion Hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 48
States / cities: Anchorage, Alaska • Hamden, Connecticut • Newark, Delaware + 41 more

Conditions: Insomnia, Nicotine Dependence
Interventions: Eszopiclone, Bupropion; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cancer Survivor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: smoking cessation intervention, bupropion hydrochloride; Behavioral · Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Drug Drug Interaction
Interventions: EPX-100, Itraconazole, Phenytoin, Omeprazole, Midazolam, Bupropion; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Chronic Kidney Diseases, Deficiency, Vitamin D
Interventions: Cholecalciferol; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Aurora, Colorado • Pittsburgh, Pennsylvania

Conditions: Methamphetamine Dependence
Interventions: Bupropion, Placebo; Drug · Other
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 9 more

Conditions: Cigarette Smoking
Interventions: Extended Care Management, Standard Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Loma Linda, California

Search by objective public record fields.

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

Wellbutrin XL Effects on SSRIs Induced Changes

Assessing Symptomatic Clinical Episodes in Depression

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression

Tobacco Use Intervention Among Radiation Oncology Patients

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

Dynamic Measures of Neurochemistry in Mood Disorders

PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

Sexual Functioning Study With Antidepressants

Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

An Open Label Trial of Bupropion and Naltrexone for Binge Drinking

Integrated Smoking Cessation Treatment for Low Income Community Corrections

Seasonal Affective Depression (SAD) Study

Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

Bupropion and Counseling With or Without Contingency Management to Enhance Smoking Cessation in Treating Cancer Survivors Who Continue to Smoke

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

Smoking Interventions for Hospital Patients

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America